About Sperm-egg fusion protein Juno
Sperm-egg fusion protein Juno (IZUMO1R) is a protein
from Homo sapiens identified by UniProt accession
A6ND01, 250 residues long.
MolForge cross-references it against 0 known binders and
58 disease associations.
Target properties
| Protein name | Sperm-egg fusion protein Juno |
|---|
| UniProt accession | A6ND01 |
|---|
| Gene | IZUMO1R |
|---|
| Organism | Homo sapiens |
|---|
| Length | 250 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (58)
Diseases linked to this target (Open Targets).
- sleep apnea measurement · score 0.20
- obstructive sleep apnea · score 0.20
- Female infertility due to fertilization defect · score 0.11
- Rare genetic female infertility · score 0.11
- female infertility due to zona pellucida defect · score 0.10
- oocyte maturation defect 11 · score 0.10
- female infertility due to oocyte meiotic arrest · score 0.10
- Hydatidiform Mole · score 0.09
- oocyte/zygote/embryo maturation arrest 17 · score 0.09
- oocyte maturation defect 9 · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A6ND01-F1 | alphafold | PREDICTED | 87.35 | — |
Amino-acid sequence (250 residues)
MACWWPLLLE LWTVMPTWAG DELLNICMNA KHHKRVPSPE DKLYEECIPW KDNACCTLTT SWEAHLDVSP LYNFSLFHCG LLMPGCRKHF IQAICFYECS PNLGPWIQPV GSLGWEVAPS GQGERVVNVP LCQEDCEEWW EDCRMSYTCK SNWRGGWDWS QGKNRCPKGA QCLPFSHYFP TPADLCEKTW SNSFKASPER RNSGRCLQKW FEPAQGNPNV AVARLFASSA PSWELSYTIM VCSLFLPFLS
Explore Sperm-egg fusion protein Juno with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets